Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to $2.5 million.

  • Lyell Immunopharma's Other Non-Current Assets rose 78368.06% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 78368.06%. This contributed to the annual value of $4.6 million for FY2024, which is 913.81% up from last year.
  • Per Lyell Immunopharma's latest filing, its Other Non-Current Assets stood at $2.5 million for Q3 2025, which was up 78368.06% from $2.5 million recorded in Q2 2025.
  • Lyell Immunopharma's Other Non-Current Assets' 5-year high stood at $4.6 million during Q4 2024, with a 5-year trough of $279000.0 in Q1 2022.
  • For the 5-year period, Lyell Immunopharma's Other Non-Current Assets averaged around $1.1 million, with its median value being $288000.0 (2024).
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first plummeted by 4012.88% in 2022, then surged by 141250.0% in 2023.
  • Lyell Immunopharma's Other Non-Current Assets (Quarter) stood at $466000.0 in 2021, then tumbled by 39.91% to $280000.0 in 2022, then skyrocketed by 1412.5% to $4.2 million in 2023, then rose by 9.14% to $4.6 million in 2024, then plummeted by 44.94% to $2.5 million in 2025.
  • Its Other Non-Current Assets was $2.5 million in Q3 2025, compared to $2.5 million in Q2 2025 and $3.2 million in Q1 2025.